Glioblastoma
📧 Sign up to get email alerts when something new happens for Glioblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) [Phase 2]
Phase II study evaluating Optune (NovoTTF) with Bevacizumab and Temozolomide in newly diagnosed unresectable glioblastoma; trial terminated …
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas [Phase 2]
Phase 2 trial evaluating selinexor (KPT-330) in recurrent gliomas was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: FMISO PET Study of Glioblastoma [NA]
Clinical trial update for a FMISO PET study in recurrent glioblastoma; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects [Phase 3]
Phase 3 safety and efficacy study of Trans Sodium Crocetinate in newly diagnosed glioblastoma biopsy-only subjects was terminated; results p…
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects [Phase 2]
Phase 2 trial evaluating combination of an oncolytic adenovirus with pembrolizumab for brain cancers has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-06Clinical Trial Update: Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. [Phase 2]
Phase II trial evaluating PF-299804 (dacomitinib), a Pan-HER irreversible inhibitor, in recurrent glioblastoma with EGFR amplification or EG…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Mathematical Model-Adapted Radiation In Glioblastoma [NA]
Clinical trial update for a study on a mathematical model-adapted radiation approach in recurrent glioblastoma; the study is completed with …
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) [Phase 1, Phase 2]
A phase 1/2 study of E7050 in combination with E7080 in advanced solid tumors and specific recurrent/unresectable cancers; the trial status …
-
CLINICAL_TRIALS trial_result · 2021-06-02Clinical Trial Update: Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma [NA]
A completed clinical trial evaluating calorie-restricted ketogenic diet and transient fasting during reirradiation for recurrent glioblastom…
-
CLINICAL_TRIALS trial_result · 2021-05-11Clinical Trial Update: Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM [Phase 2, Phase 3]
Phase II/III trial update for concurrent chemoradiotherapy with or without JP001 in newly diagnosed glioblastoma.
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) [Phase 2]
A Phase 2 clinical trial update for MBM-02 (Tempol) investigating treatment for glioblastoma/ glioblastoma multiforme is listed as status UN…
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: Antisecretory Factor in Primary Glioblastoma 1 [Phase 1, Phase 2]
Phase 1/2 trial evaluating antisecretory factor for glioblastoma and associated cerebral edema has completed.
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme [Phase 2, Phase 3]
Phase II/III study evaluating high-dose, intermittent sunitinib for recurrent glioblastoma multiforme is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2021-04-15Clinical Trial Update: A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma [Phase 2]
Phase 2 trial investigating high-dose chemoradiation with biologically-based target volume definition in glioblastoma.
-
CLINICAL_TRIALS trial_result · 2021-04-02Clinical Trial Update: Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma [Phase 3]
Phase 3 trial investigating neoadjuvant temozolomide with simultaneous IMRT for glioblastoma.
-
CLINICAL_TRIALS trial_result · 2021-03-26Clinical Trial Update: Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma [EARLY_Phase 1]
Phase 0 analysis of ixazomib (MLN9708) in patients with glioblastoma; early-phase study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-24Clinical Trial Update: HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM [Phase 2]
Phase 2 trial update for HSPPC-96 vaccine with temozolomide in newly diagnosed glioblastoma multiforme patients; study completed with posted…
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: Disulfiram in Recurrent Glioblastoma [Phase 2, Phase 3]
Clinical trial update for disulfiram in recurrent glioblastoma, reporting Phase 2 and Phase 3 results; study status is completed.
-
CLINICAL_TRIALS trial_result · 2021-03-03Clinical Trial Update: Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma [Phase 2]
Phase II study of combined temozolomide and SGT-53 for recurrent glioblastoma has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-26Clinical Trial Update: Chloroquine for Glioblastoma. [Phase 1, Phase 2]
A clinical trial update investigating chloroquine for glioblastoma across Phase 1 and Phase 2 stages.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) [Phase 3]
A Phase 3 trial comparing nivolumab versus temozolomide, each with radiation, in newly diagnosed glioblastoma; study completed with results …
-
CLINICAL_TRIALS trial_result · 2021-02-01Clinical Trial Update: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma [Phase 2]
Phase 2 trial evaluating SurVaxM vaccine therapy in combination with temozolomide for newly diagnosed glioblastoma (including gliosarcoma); …
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma [Phase 1]
Phase 1 trial evaluating CMV RNA-pulsed dendritic cells in pediatric and young adult patients with recurrent malignant glioma and related br…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma [Phase 2]
Phase 2 trial evaluating safety of TTAC-0001 (Tanibirumab) in patients with recurrent glioblastoma has been completed.
-
CLINICAL_TRIALS trial_result · 2021-01-26Clinical Trial Update: Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma [Phase 2]
Phase 2 trial update evaluating anlotinib with STUPP for MGMT-unmethylated glioblastoma is underway, with status currently unknown.